Navidea Biopharmaceuticals to Present at 2014 Biotech Showcase™ Conference

Download as PDF

– CEO to Provide Business, Commercial and Development Program Updates –

DUBLIN, Ohio--(BUSINESS WIRE)-- Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB), a biopharmaceutical company focused on precision diagnostic radiopharmaceuticals, today announced that Dr. Mark Pykett, VMD PhD, Navidea Chief Executive Officer, and other members of Navidea management will participate in the 2014 Biotech Showcase Conference from January 13-15, 2014 held at the Parc 55 Wyndham-Union Square in San Francisco, CA. Dr. Pykett will provide an update of the Company and its commercial and development programs on Monday, January 13, 2014 at 11:00 AM PST in the Powell Room.

Investors and the public are invited to listen to a live webcast of Dr. Pykett’s presentation at http://www.media-server.com/m/p/etqv5fpu. Following the conference, the webcast will be archived for approximately 30 days.

About Navidea Biopharmaceuticals, Inc.
Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB) is a biopharmaceutical company focused on the development and commercialization of precision diagnostics and radiopharmaceutical agents. Navidea is developing multiple precision diagnostic products and platforms including NAV4694, NAV5001, Manocept™ and RIGScanTM, to help identify the sites and pathways of undetected disease and enable better diagnostic accuracy, clinical decision-making and, ultimately, patient care. Lymphoseek® (technetium 99m tilmanocept) Injection, Navidea’s first commercial product from the Manocept platform, was approved by the FDA in March 2013. Navidea’s strategy is to deliver superior growth and shareholder return by bringing to market novel radiopharmaceutical agents and advancing the Company’s pipeline through selective acquisitions, global partnering and commercialization efforts. For more information, please visit www.navidea.com.

Navidea Biopharmaceuticals
Brent Larson, Executive VP & CFO, 614-822-2330
or
Sharon Correia, Associate Director, Corporate Communications, 978-655-2686

Source: Navidea Biopharmaceuticals, Inc.

Released January 7, 2014